# A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China

> **NCT04477772** · PHASE1 · COMPLETED · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 71 (actual)

## Conditions studied

- Recurrent/Refractory Malignant Lymphoma

## Interventions

- **BIOLOGICAL:** JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion
- **BIOLOGICAL:** Drug：JS001, Intravenous infusion

## Key facts

- **NCT ID:** NCT04477772
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-17
- **Primary completion:** 2024-03-14
- **Final completion:** 2024-03-14
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04477772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04477772, "A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04477772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*